We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Begins Granting Five-Year Exclusivity for More Fixed-Dose Combo Drugs
FDA Begins Granting Five-Year Exclusivity for More Fixed-Dose Combo Drugs
The FDA has expanded market exclusivity from three to five years on all fixed-dose combination drugs that contain a new active ingredient, bowing to industry pressure for new incentives to develop the costly products.